Research presented at the European Renal Association Congress suggests that dihydropyridine calcium-channel blockers may elevate the risk of kidney complications in patients with type 2 diabetes, prompting calls for careful review of blood pressure treatments.
A study presented at the European Renal Association Congress has raised fresh concerns about a widely used class of blood pressure drugs in people with type 2 diabetes and existing kidney risk. Researchers tracking more than 31,000 adults found that dihydropyridine calcium-channel blockers, a group that includes amlodipine, were linked with a 33% higher risk of major kidney complications than other blood pressure treatments.
The findings are notable because every patient in the analysis was already receiving therapies regarded as standard care for diabetic kidney disease: renin-angiotensin system inhibitors and SGLT2 inhibitors, a newer class of diabetes drugs that also help protect the kidneys. Even with those medications in place, the increased risk remained, according to the study as reported in PubMed and coverage by Drugs.com.
The main outcome measured was serious decline in kidney function, including a fall of at least 40% in estimated glomerular filtration rate, progression to end-stage kidney disease, dialysis or transplantation. Over a median follow-up of about 3.5 years, the difference held after adjustment for other factors. Researchers said the most likely explanation is that these medicines may alter pressure within the kidney’s filtering units, potentially adding strain to tissue already damaged by diabetes.
That interpretation fits earlier work too. A separate nationwide study published in PubMed found DCCB use was associated with faster chronic kidney disease progression in people with diabetes, while another study reported increased risk of severe albuminuria and kidney failure in some patients starting these drugs without renin-angiotensin system blockade. A review in Nature also noted that the role of calcium-channel blockers in kidney disease has remained unsettled.
The practical message is not to stop treatment abruptly, but to review it carefully. Blood pressure control remains central to protecting kidney health in diabetes, and the study does not prove the drugs caused the damage. Still, because DCCBs are so commonly prescribed, the authors said the association could matter for large numbers of patients and should prompt a closer look at how blood pressure regimens are chosen in the context of kidney disease.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
